Anti-proliferative agents for treating pah
AssigneePfizer Inc.
InventorSteven Martin Evans
Life of this patent
Estimating the term…
Abstract
Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
Claims21
A method for treating PAH in a subject in need thereof, which method comprise administering to the subject an effective amount of 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
A method for treating a disease or disorder in a human or animal in need thereof, which method comprises administering to the human or animal an effective amount of 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof, wherein the disease or disorder is selected from the group consisting of PCH, pulmonary hypertension due to left heart disease, pulmonary hypertension due to lung disease or hypoxia, chronic thromboembolic pulmonary hypertension, pulmonary hypertension with unclear or multifactorial etiologies, idiopathic forms of pulmonary vascular disease, a lung disorder, and primary lung vascular disorders.
A method for treating PAH in a subject in need thereof, which method comprises administering to the subject an effective amount of a CDK inhibitor.
20-24. (canceled)
Dependencies are inferred from the claim text.